<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763412</url>
  </required_header>
  <id_info>
    <org_study_id>05-1109</org_study_id>
    <secondary_id>P60DK020579</secondary_id>
    <nct_id>NCT00763412</nct_id>
  </id_info>
  <brief_title>Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis</brief_title>
  <official_title>Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbelaez, Ana Maria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbelaez, Ana Maria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide the necessary data and experience to design a larger,
      full scale clinical trial to determine if a certain medicine (repaglinide), which increases
      the amount of insulin secreted by the pancreas, can improve the nutritional status and
      pulmonary function of adolescents and young adults with cystic fibrosis and prediabetes by
      improving blood glucose control. The investigators are also trying to determine the
      relationship between systemic inflammatory factors and glucose impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As people with Cystic Fibrosis (CF) are living well into adulthood new complications are
      arising. CF-Related Diabetes (CFRD) has emerged as a major complication. Years prior to the
      diagnosis of CFRD, patients have decreasing insulin secretion, glucose intolerance,
      deteriorating pulmonary function, and nutritional impairment. There are no current standard
      recommendations for the treatment of CF patients with prediabetes, and there is little
      evidence that treatment of this prediabetic state in CF patients will prevent the
      deterioration of the lung function, nutritional status and potentially slow the progression
      to manifest CFRD.

      To determine the feasibility of testing this hypothesis, we will perform a pilot,
      double-blinded, randomized controlled trial in 20 CF pancreatic insufficient patients ages of
      12 to 24 years old with impaired glucose tolerance test (IGT) or CFRD without fasting
      hyperglycemia (CFRD-No FH) and assign them to either placebo or Repaglinide 0.5 mg PO 3 - 4
      times a day before meals for two years. Patients will monitor their blood glucose daily and
      will be followed every 3 months for 2 years to determine changes in nutritional status by BMI
      and DEXA, lung function tests, frequency of hospitalizations, antibiotic courses, and degree
      of glucose tolerance, insulin secretion and insulin sensitivity.

      In addition, based on the evidence of increased inflammation in type 2 diabetes, correlation
      of systemic inflammatory response at different degrees of glucose tolerance and after
      treatment, will be assessed in these subjects, as well as in another 20 CF pancreatic
      insufficient matched patients with normal glucose tolerance who will be studied once without
      intervention
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>2 year/end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Composition</measure>
    <time_frame>2 year/end of study</time_frame>
    <description>Reporting % of Fat and Lean body mass</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CRP</measure>
    <time_frame>2 year/end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose Tolerance</measure>
    <time_frame>2-year</time_frame>
    <description>We completed the OGTT at the 2 year/end of study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>2 year/end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wt Z Score</measure>
    <time_frame>2 year/end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tanner Stage</measure>
    <time_frame>2 year/end of study</time_frame>
    <description>Puberty scale measuring 1-5, 1 being least development, 5 being most development.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV 1</measure>
    <time_frame>2 year/end of study</time_frame>
    <description>% of lung function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Peptide</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Cystic Fibrosis Related Diabetes</condition>
  <condition>Pancreatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 pill before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance. Subjects were randomized to placebo or drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. repaglinide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>repaglinide 0.5 mg before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance.Subjects were randomized to placebo or drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
    <arm_group_label>1 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>repaglinide</intervention_name>
    <description>CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
    <arm_group_label>2. repaglinide</arm_group_label>
    <other_name>Prandin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or females 12 -24 years old

          -  Diagnosis of Cystic Fibrosis by sweat test with exocrine pancreatic insufficiency

          -  Must have a glucose pattern by Oral Glucose Tolerance Test with fasting blood glucose
             &lt;126 mg/dl and 2 hour: 140 - 199 mg/dl or &gt;200 mg/dl.

          -  Weight must be stable within 5% for 3 months prior to initiation visit

          -  Must be able to reproducibly perform spirometry based on American Thoracic Society
             guidelines

        Exclusion Criteria:

          -  Patients receiving growth hormone therapy or taking insulin

          -  Patients with evidence of liver dysfunction

          -  Patients who are status-post lung or liver transplantation

          -  Patients who have received systemic steroids for more than 28 days during the 6 months
             prior to the study

          -  Patients with active ABPA on steroids

          -  Patients taking medications that affect glucose metabolism or contraindicated with
             repaglinide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil H White, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2008</study_first_submitted>
  <study_first_submitted_qc>September 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2008</study_first_posted>
  <results_first_submitted>July 11, 2016</results_first_submitted>
  <results_first_submitted_qc>May 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2017</results_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Arbelaez, Ana Maria</investigator_affiliation>
    <investigator_full_name>Ana Maria Arbelaez</investigator_full_name>
    <investigator_title>Assistant Professor in Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Cystic Fibrosis Related Diabetes</keyword>
  <keyword>Pre-diabetes</keyword>
  <keyword>oral hypoglycemic agents</keyword>
  <keyword>Repaglinide</keyword>
  <keyword>treatment</keyword>
  <keyword>inflammatory markers</keyword>
  <keyword>Lung function</keyword>
  <keyword>nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Repaglinide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The outcome was inconclusive for this hypothesis, but the data may be valuable in future research. We are not currently sharing data from this project.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>1 pill before each meal 3-4 times a day for 2 years.
placebo: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
        </group>
        <group group_id="P2">
          <title>2. Repaglinide</title>
          <description>repaglinide 0.5 mg before each meal 3-4 times a day for 2 years.
repaglinide: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients attended the Washington University CF Clinics between 2006 and 2008.</population>
      <group_list>
        <group group_id="B1">
          <title>Patients Who Received Placebo</title>
          <description>All participants were receiving ADEK vitamins and pancreatic enzyme replacement. Patients were required to be clinically stable, without evidence of deterioration from previous pulmonary function tests (PFTs) for 3-months prior to the study and without CF exacerbation or hospitalization for 2-months prior to the study. Additionally, patients were required to have maintained stable weight within 5% variance for 3-months prior to participation. Exclusion criteria included fasting blood glucose levels &gt;126 mg/dL on study day, IV antibiotic or systemic steroid use within two months, oral corticosteroid usage for more than 28-days over the past 6-months, history of lung or liver transplant, elevated transaminases, allergic bronchopulmonary aspergillosis, or the inability to perform spirometry.</description>
        </group>
        <group group_id="B2">
          <title>Patients Who Received Repaglinide</title>
          <description>All participants were receiving ADEK vitamins and pancreatic enzyme replacement. Patients were required to be clinically stable, without evidence of deterioration from previous pulmonary function tests (PFTs) for 3-months prior to the study and without CF exacerbation or hospitalization for 2-months prior to the study. Additionally, patients were required to have maintained stable weight within 5% variance for 3-months prior to participation. Exclusion criteria included fasting blood glucose levels &gt;126 mg/dL on study day, IV antibiotic or systemic steroid use within two months, oral corticosteroid usage for more than 28-days over the past 6-months, history of lung or liver transplant, elevated transaminases, allergic bronchopulmonary aspergillosis, or the inability to perform spirometry.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Patients attended the Washington University CF Clinics between 2006 and 2008.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="12" upper_limit="18"/>
                    <measurement group_id="B2" value="15" lower_limit="12" upper_limit="22"/>
                    <measurement group_id="B3" value="15.5" lower_limit="12" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.45" lower_limit="14.55" upper_limit="22.96"/>
                    <measurement group_id="B2" value="18.38" lower_limit="16.78" upper_limit="20.3"/>
                    <measurement group_id="B3" value="18.94" lower_limit="14.55" upper_limit="22.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wt Z score</title>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.11" lower_limit="-1.84" upper_limit="0.33"/>
                    <measurement group_id="B2" value="-0.29" lower_limit="-0.75" upper_limit="0.19"/>
                    <measurement group_id="B3" value="-0.7" lower_limit="-1.84" upper_limit=".33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat %</title>
          <units>% Fat mass</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.34" lower_limit="7.36" upper_limit="38.74"/>
                    <measurement group_id="B2" value="22.06" lower_limit="9.76" upper_limit="28.81"/>
                    <measurement group_id="B3" value="21.2" lower_limit="7.36" upper_limit="38.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lean %</title>
          <units>% Lean mass</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.71" lower_limit="58.6" upper_limit="89.67"/>
                    <measurement group_id="B2" value="75" lower_limit="68.22" upper_limit="87.11"/>
                    <measurement group_id="B3" value="75.9" lower_limit="58.6" upper_limit="89.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tanner stage</title>
          <description>This is a measurement of puberty development. This is a 1-5 scale describing 1 as the least developed and 5 as the most developed in puberty.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.75" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="B2" value="3.25" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="B3" value="3.5" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV 1</title>
          <units>% of lung function</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.75" lower_limit="92" upper_limit="121"/>
                    <measurement group_id="B2" value="92.75" lower_limit="70" upper_limit="105"/>
                    <measurement group_id="B3" value="95.25" lower_limit="70" upper_limit="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Glucose</title>
          <description>This was the baseline glucose in a 2 hour oral glucose tolerance test. (OGTT)</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99.1" lower_limit="87" upper_limit="114.5"/>
                    <measurement group_id="B2" value="100" lower_limit="94" upper_limit="106"/>
                    <measurement group_id="B3" value="99.6" lower_limit="87" upper_limit="114.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2 hour glucose</title>
          <description>Final glucose sample in a 2 hour OGTT.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182.4" lower_limit="144" upper_limit="218.5"/>
                    <measurement group_id="B2" value="183" lower_limit="140" upper_limit="206"/>
                    <measurement group_id="B3" value="182.7" lower_limit="140" upper_limit="218.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting C-Peptide</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.2" lower_limit="0.6" upper_limit="2.1"/>
                    <measurement group_id="B2" value="1.7" lower_limit="1.0" upper_limit="3"/>
                    <measurement group_id="B3" value="1.45" lower_limit="0.6" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2 hour c-peptide</title>
          <description>final c-peptide measurement at the end of 2 hour OGTT.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.7" lower_limit="6" upper_limit="15.5"/>
                    <measurement group_id="B2" value="9.5" lower_limit="5" upper_limit="12.6"/>
                    <measurement group_id="B3" value="9.6" lower_limit="5" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Inflammatory marker</title>
          <description>baseline values collected during a 2 hour OGTT.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>IL1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.1" lower_limit="0.1" upper_limit="1.9"/>
                    <measurement group_id="B2" value="0.9" lower_limit=".01" upper_limit="1.7"/>
                    <measurement group_id="B3" value="0.5" lower_limit="0.1" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" lower_limit="1.5" upper_limit="26.4"/>
                    <measurement group_id="B2" value="12.6" lower_limit="3.7" upper_limit="33.8"/>
                    <measurement group_id="B3" value="10.5" lower_limit="1.5" upper_limit="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="2.7" upper_limit="17.8"/>
                    <measurement group_id="B2" value="8.5" lower_limit="4.6" upper_limit="13.6"/>
                    <measurement group_id="B3" value="7.75" lower_limit="2.7" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF Alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" lower_limit="5.2" upper_limit="7.3"/>
                    <measurement group_id="B2" value="4.5" lower_limit="2.5" upper_limit="6.4"/>
                    <measurement group_id="B3" value="5.9" lower_limit="2.5" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CRP</title>
          <description>inflammatory marker</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" lower_limit="0.2" upper_limit="2.5"/>
                    <measurement group_id="B2" value="2.1" lower_limit="0.8" upper_limit="3.3"/>
                    <measurement group_id="B3" value="1.95" lower_limit="0.2" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BMI</title>
        <time_frame>2 year/end of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo</title>
            <description>1 pill before each meal 3-4 times a day for 2 years.
placebo: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>2. Repaglinide</title>
            <description>repaglinide 0.5 mg before each meal 3-4 times a day for 2 years.
repaglinide: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>BMI</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.63" lower_limit="15.56" upper_limit="22.64"/>
                    <measurement group_id="O2" value="21.19" lower_limit="20.78" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Composition</title>
        <description>Reporting % of Fat and Lean body mass</description>
        <time_frame>2 year/end of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo</title>
            <description>1 pill before each meal 3-4 times a day for 2 years.
placebo: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>2. Repaglinide</title>
            <description>repaglinide 0.5 mg before each meal 3-4 times a day for 2 years.
repaglinide: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition</title>
          <description>Reporting % of Fat and Lean body mass</description>
          <units>% body mass</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.82" lower_limit="12" upper_limit="37.8"/>
                    <measurement group_id="O2" value="26.21" lower_limit="8.78" upper_limit="34.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.15" lower_limit="59.54" upper_limit="87.84"/>
                    <measurement group_id="O2" value="70.83" lower_limit="62.82" upper_limit="87.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CRP</title>
        <time_frame>2 year/end of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo</title>
            <description>1 pill before each meal 3-4 times a day for 2 years.
placebo: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>2. Repaglinide</title>
            <description>repaglinide 0.5 mg before each meal 3-4 times a day for 2 years.
repaglinide: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>CRP</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="0.7" upper_limit="27.5"/>
                    <measurement group_id="O2" value="2" lower_limit="0.6" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Tolerance</title>
        <description>We completed the OGTT at the 2 year/end of study visit.</description>
        <time_frame>2-year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo</title>
            <description>1 pill before each meal 3-4 times a day for 2 years.
placebo: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>2. Repaglinide</title>
            <description>repaglinide 0.5 mg before each meal 3-4 times a day for 2 years.
repaglinide: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Tolerance</title>
          <description>We completed the OGTT at the 2 year/end of study visit.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fasting glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.5" lower_limit="91" upper_limit="121"/>
                    <measurement group_id="O2" value="94.5" lower_limit="85" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.75" lower_limit="145" upper_limit="258"/>
                    <measurement group_id="O2" value="184" lower_limit="123" upper_limit="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Markers</title>
        <time_frame>2 year/end of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo</title>
            <description>1 pill before each meal 3-4 times a day for 2 years.
placebo: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>2. Repaglinide</title>
            <description>repaglinide 0.5 mg before each meal 3-4 times a day for 2 years.
repaglinide: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Markers</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.13" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.34" lower_limit="0.13" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="0.54" upper_limit="28.6"/>
                    <measurement group_id="O2" value="6" lower_limit="2.2" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="3.59" upper_limit="10.79"/>
                    <measurement group_id="O2" value="5.2" lower_limit="3.1" upper_limit="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="2.05" upper_limit="7.5"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.99" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wt Z Score</title>
        <time_frame>2 year/end of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo</title>
            <description>1 pill before each meal 3-4 times a day for 2 years.
placebo: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>2. Repaglinide</title>
            <description>repaglinide 0.5 mg before each meal 3-4 times a day for 2 years.
repaglinide: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Wt Z Score</title>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" lower_limit="-1.94" upper_limit="0.08"/>
                    <measurement group_id="O2" value="-0.26" lower_limit="-0.31" upper_limit="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tanner Stage</title>
        <description>Puberty scale measuring 1-5, 1 being least development, 5 being most development.</description>
        <time_frame>2 year/end of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo</title>
            <description>1 pill before each meal 3-4 times a day for 2 years.
placebo: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>2. Repaglinide</title>
            <description>repaglinide 0.5 mg before each meal 3-4 times a day for 2 years.
repaglinide: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Tanner Stage</title>
          <description>Puberty scale measuring 1-5, 1 being least development, 5 being most development.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV 1</title>
        <description>% of lung function</description>
        <time_frame>2 year/end of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo</title>
            <description>1 pill before each meal 3-4 times a day for 2 years.
placebo: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>2. Repaglinide</title>
            <description>repaglinide 0.5 mg before each meal 3-4 times a day for 2 years.
repaglinide: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV 1</title>
          <description>% of lung function</description>
          <units>% lung function</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" lower_limit="71" upper_limit="99"/>
                    <measurement group_id="O2" value="91.5" lower_limit="74" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-Peptide</title>
        <time_frame>2 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo</title>
            <description>1 pill before each meal 3-4 times a day for 2 years.
placebo: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
          <group group_id="O2">
            <title>2. Repaglinide</title>
            <description>repaglinide 0.5 mg before each meal 3-4 times a day for 2 years.
repaglinide: CF pancreatic insufficient patients with prediabetes by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>C-Peptide</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fasting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.8" upper_limit="2.3"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.6" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="5" upper_limit="8.7"/>
                    <measurement group_id="O2" value="7.7" lower_limit="4.2" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This pilot study was designed to collect data over a 2 year time period.</time_frame>
      <desc>Glucose diaries, and food diaries were reviewed, and safety labs were collected at each visit. Physical assessments by the PI were completed as well.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo group of CF pancreatic insufficient patients ages 12-24 years old with impaired glucose tolerance test (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH).</description>
        </group>
        <group group_id="E2">
          <title>Repaglinide</title>
          <description>Repaglinide intervention group of CF pancreatic insufficient patients ages 12-24 years old with impaired glucose tolerance test (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation of the study was the very small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ana Maria Arbelaez</name_or_title>
      <organization>Washington University in St Louis</organization>
      <phone>314-286-1138</phone>
      <email>arbelaez_a@kids.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

